Streetbeat News

Stock Prices

CWT

California Water Service Group (NYSE:CWT) reported Q2 2024 GAAP EPS of $0.70, beating the analyst estimate of $0.44 by 59.09%. However, sales of $244.30 million missed the estimate of $216.25 million, representing a 100% decrease from $194.04 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 1:01 pm

TMDX

Over the past three months, six analysts have shared their insights on TransMedics Gr (NASDAQ:TMDX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $160.17, with a high estimate of $200.00 and a low estimate of $120.00. Analysts have raised their price targets in response to the company's strong financial performance, including a 133.07% revenue growth rate and a net margin of 12.59%.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

ENTG

Analysts have provided mixed ratings for Entegris (NASDAQ:ENTG) in the latest quarter, with a majority being bullish. The average 12-month price target is $152.17, reflecting a slight increase from the previous target. Despite positive analyst sentiment, Entegris faces challenges in revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

KKR

KKR (NYSE:KKR) received mixed analyst ratings over the last quarter, with a majority being bullish. The average 12-month price target increased to $125.38. KKR's financials show strong revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

WRBY

Analysts have provided mixed reviews on Warby Parker (NYSE:WRBY) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target has increased to $16.6, with a high of $19.00 and a low of $14.00. Recent evaluations show some analysts raising their price targets, reflecting a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

NBIX

Over the past three months, 7 analysts have shared their insights on Neurocrine Biosciences (NASDAQ:NBIX), with ratings ranging from bullish to bearish. The average 12-month price target is $168.29, with a high of $193.00 and a low of $152.00. Recent analyst actions include maintaining or raising ratings and price targets, reflecting positive sentiment. Neurocrine Biosciences has shown strong financial performance with a 22.57% revenue growth rate, a net margin of 8.42%, and a debt-to-equity ratio of 0.21.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

FMC

FMC shares are trading higher following the release of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:58 pm

LNC

Lincoln National shares are trading higher following better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:57 pm

AMZN

DIS

IVE

IWD

NFLX

Disney plans to cut 140 jobs in its TV division, focusing on streaming investments. NatGeo and Freeform will see significant staff reductions. Disney's entertainment TV networks contributed 12% of total revenue last quarter. Meanwhile, Disney's 'Deadpool & Wolverine' movie set a record for an R-rated film. Amazon Prime Video and Netflix dominate the U.S. SVOD market.

Portfolio Pulse from Anusuya Lahiri

August 01, 2024 | 12:57 pm

RGR

Sturm, Ruger & Co shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:56 pm